Tuberculosis (TB) is the leading infectious cause of death worldwide, and the commonest cause of death in people living with HIV. Globally, pleural TB remains one of the most frequent causes of pleural exudates, particularly in TB-endemic areas and in the HIV positive population. Most TB pleural effusions are exudates with high adenosine deaminase (ADA), lymphocyte-rich, straw-coloured and free flowing, with a low yield on mycobacterial culture. TB pleurisy can also present as loculated neutrophilpredominant effusions which mimic parapneumonic effusions. Rarely, they can present as frank TB empyema, containing an abundance of mycobacteria. Up to 80% of patients have parenchymal involvement on chest imaging. The diagnosis is simple if M. tuberculosis is detected in sputum, pleural fluid or biopsy specimens, and the recent advent of liquid medium culture techniques has increased the microbiological yield dramatically. Where the prevalence of TB is high the presence of a lymphocytepredominant exudate with a high ADA has a positive predictive value of 98%. In low prevalence areas, the absence of an elevated ADA and lymphocyte predominance makes TB very unlikely, and pleural biopsy should be performed to confirm the diagnosis. Pleural biopsy for liquid culture and susceptibility testing must also be considered where the prevalence of drug resistant TB is high. Treatment regimens are identical to those administered for pulmonary TB. Initial pleural drainage may have a role in symptom relief and in hastening the resolution of the effusion. Surgical intervention may be required in loculated effusions and empyemas. In this review, we will provide an overview of pleural TB pathogenesis, clinical features, imaging, diagnosis and management, as well as highlight any new data in the field.
| IN TRO DUCT IO N
Known to man since prehistoric times, tuberculosis (TB) is currently the leading cause of death from a single infectious agent, outranking even HIV/AIDS. Worldwide, approximately 1.7 billion people are infected, with an estimated 10.4 million new cases and over 1.6 million deaths attributable to the disease in 2016. 1 In recent years TB control has been threatened by increasing emergence of drug resistance. 2 Globally, approximately 20% of isolates are resistant to at least one major anti-TB drug. 2 Twenty-five percent of adults with TB initially present with the extra-pulmonary form, in whom TB of the pleura is the second commonest site of involvement following lymph node TB. 3 Pleural TB is one of the most frequent causes of pleural exudates globally. 3 In the first world, 3%-5% of TB patients have pleural disease, 4 and in TBendemic areas the rate of pleural involvement can be as high as 30%. 5 TB remains the number one cause of death in people living with HIV. 1 In the HIV-infected population TB pleuritis is the most common cause of a lymphocytic effusion, 3 and the pleura is the primary site of infection in 30% of patients. 5 In this review, we will provide an overview of pleural TB pathogenesis, clinical features, imaging, diagnosis and management, as well as highlight any new data in the field.
| P AT HOG ENES I S OF P L EURA L TU BERC ULO S IS
The acid-fast obligate aerobe Mycobacterium tuberculosis (Mtb) is responsible for most cases of TB with a small proportion attributable to Mycobacterium africanum or to zoonotic members of the Mtb complex, such as Mycobacterium bovis or Mycobacterium caprae. 6 Mtb is a slow growing organism with a doubling-time of 14-96 h. Mtb is particular in that it develops drug resistance only by mutations and the relatively low spontaneous mutation rates (2.56 3 10 28 for isoniazid, 2.56 3 10 27 for ethambutol and 2.25 3 10 210 for rifampin) allow control of the infection with a four-drug regimen, given susceptibility to all agents. 2 The introduction of liquid culture media has increased the yield of Mtb from pleural fluid and tissue samples and led to a revision of the prevailing theory on the pathogenesis of TB pleural effusions. These effusions were previously thought to be purely a T-helper type 1 (Th1) cell-mediated delayed hypersensitivity reaction due to the entry of mycobacterial antigen into the pleural space from ruptured subpleural caseous foci. However, recent evidence has demonstrated that they may also be paucibacilliary infections which most likely spread directly from associated parenchymal lesions. 7 Evidence for the delayed hypersensitivity response as a mechanism for the effusion includes: the development of an exudative pleural effusion on introduction of TB antigen into the pleural space of guinea pigs sensitised to purified protein derivative; and suppression of pleural effusion development by the administration of antilymphocyte serum in the same guinea pig model; the low yield of Mtb from pleural fluid culture in historic literature; the lymphocyte predominance of the majority of fluid aspirates with a high proportion of Th cells compared to blood; and raised gamma interferon levels and Th1-related cytokines (eg, IL-12) within pleural fluid. [7] [8] [9] [10] [11] Evidence which supports direct pleural infection as the mechanism of development includes: microbiological evidence of pulmonary disease in many cases; studies demonstrating a pleural fluid culture positivity rate for Mtb of up to 76%; evidence that a significant proportion of TB effusions are neutrophilic at least at an early stage; the identification of a negative association between lymphocyte percentage in pleural fluid and the probability of a positive effusion culture suggesting a process of infection and clearance; and a higher mycobacterial burden in effusions that have loculations. 7, 12 It has previously been demonstrated that the initial response to TB in the pleura is a rapid influx of polymorphonuclear leukocytes, particularly neutrophils which remain the predominant cells for the first 24 h, followed by macrophages, which peak at 96 h, and then by lymphocytes. 3 A recent theory postulates a 'continuous spectrum of tuberculous pleurisy' suggesting that TB empyemas are lymphocyte predominant at the time of initial testing, and as the disease progresses the fluid becomes predominantly neutrophilic, with the development of loculations, and positive effusion cultures. 12 Fluid accumulation in the pleural space results predominantly from increased capillary permeability due to the inflammatory reaction with subsequent protein influx. The high protein content of the fluid stimulates a higher rate of pleural fluid formation, and the occlusion of pleural lymphatic stomata from the lymphocytic pleuritic results in a decreased fluid clearance rate.
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| CL IN I CAL F E ATUR ES
Pleural TB can be both primary TB and reactivation disease. 4 It more commonly affects younger than older patients, however, the age of presentation tends to be higher where the mechanism is predominantly reactivation TB, as in nonendemic countries 14, 15 TB pleuritis should be suspected in any patient with a unilateral pleural effusion of any size. 13, 14 It typically presents as an acute illness with fever (75%), pleuritic chest pain (50%-75%) and a nonproductive cough (70%-75%). Over two-thirds of patients are symptomatic for less than 1 month, with the remainder symptomatic for less than 1 week. 4, 13 Additional presenting features include night sweats (50%), chills, weakness, dyspnoea (50%) and weight loss (25%-85%). 4 The natural history of the effusion is a slow resolution without treatment, however, up to 65% will progress to active TB within 5 years. 16, 17 The development of active pulmonary TB after resolution of a pleural effusion is independent of pleural fluid culture positivity, the initial size, or the presence of residual pleural abnormalities. 16 TB pleural effusions are more common in HIV positive patients. 14 This population has been found to be slightly older than HIV negative patients with TB pleuritis, and show a higher incidence of disseminated disease at presentation. 13 They have a longer duration of illness, and a lower incidence of chest pain. 14 Clinical features include a higher rate of systemic signs and symptoms such as fever, night sweats, fatigue, diarrhoea, tachypnoea, hepatosplenomegaly and lymphadenopathy. 13 In contradistinction, the rates of pleural TB in the immunosuppressed renal transplant and dialysis populations are low.
18,19
| TB E MP Y EMA
Chronic active infection in the pleural space results in a purulent TB effusion which consists largely of neutrophils. This may develop through various mechanisms: progression of primary TB pleuritis as suggested above, direct spread of infection into the pleural space from ruptured thoracic lymph nodes or a subdiaphragmatic focus, haematogenous spread, post pneumonectomy, or historically following therapeutic pneumothorax that lead to lung entrapment. 13 The empyema evolves through 3 stages: Stage I-the pre-empyema exudative phase characterised by a clear, viscous, sterile pleural effusion; Stage II-the fibrinopurulent phase, in which the fluid becomes thick, infected and purulent; Stage III-the organising or consolidation phase, involving the formation of granulation tissue and lung encasement. 20 The majority of TB empyemas will leave a thickened scarred calcified pleura. 21 
| COM P LI CAT IO NS
Empyema necessitans (necessitatis) occurs when there is extension of purulent fluid through the parietal pleura into the chest wall. 22, 23 A TB pleural effusion with severe concomitant parenchymal involvement can cause an alveolarpleural or broncho-pleural fistula, with subsequent secondary spontaneous pneumothorax and empyema. 20 The development of a persistent air leak in this situation is not unusual, especially in the presence of significant pleural adhesions. 24 Residual pleural fibrosis or fibrothorax occurs in 5%-55% of patients, and pleural thickening of > 10 mm may be associated with significant lung function impairment, dyspnoea and chronic chest pain.
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| IM AG IN G
TB pleural effusions are usually unilateral, and vary in size.
14 One large observational study found TB pleural effusions occupied more than two-thirds of the hemithorax in 18.5% of patients, between one third and two thirds in 47.2% of patients, and less than one third in 34.2% of patients. 28 TB accounted for 12% of massive pleural effusions in another study. 29 The rate of concomitant parenchymal involvement on chest radiography is 20%-50%, and there will invariably be infiltrates ipsilateral to the effusion which may only become visible on drainage of the effusion and re-expansion of the lung (Figure 1) . 15, 30 Computed tomography (CT) of the chest improves visualisation of parenchymal involvement, increasing the rate of concomitant parenchymal disease (most commonly micronodules in both the subpleural and peribronchovascular interstitium, with interlobular septal thickening) up to 80% of cases ( Figure 2 ). 31 CT can be used for quantification of pleural thickening, and detection of complications. 13 The characteristic ultrasonographic finding of a TB effusion is a free flowing effusion, however, the appearance can vary widely from an anechoic effusion, to a complex septated effusion, or even a homogeneously echogenic effusion in the case of empyema. 32 Ultrasonography should be used to guide thoracentesis and closed pleural biopsies for safety purposes, though its use does not materially affect the diagnostic yield. [32] [33] [34] In images acquired via thoracoscopy, the presence of sago-like nodules and adhesions would suggest TB. , however, its use in other contexts is limited. 35 
| Adenosine deaminase
Adenosine deaminase (ADA) is a purine-degrading enzyme found predominantly in T-lymphocytes, responsible for the conversion of adenosine and deoxyadenosine to inosine and deoxyinosine. The enzyme has two isoforms: ADA1 which is found in all cells but particularly in lymphocytes and monocytes, and ADA2 which is only in monocytes. ADA2 is the predominant isoform in TB pleural effusions.
14 This inexpensive colorimetric test is favoured in high TB endemic regions for its high positive predictive value (PPV). 14 In these areas, a value of more than 40IU/L in conjunction with a lymphocyte predominant pleural effusion and a clinical suspicion of TB infection carries a PPV of 98% and is considered sufficient evidence for the initiation of anti-TB treatment. 36, 37 ADA levels are also elevated in the pleural fluid of HIV positive patients, irrespective of CD4 count. 38 In non-TB endemic areas (and patients without significant exposure acquired elsewhere), the ADA is used to rule out TB pleural disease. 36, 37 Using a cut-off value of 30 IU/L, it had a negative predictive value (NPV) of 98.9% in a recent study. 39 In a meta-analysis, the sensitivity, specificity, positive likelihood ratio, negative likelihood ratio and diagnostic odds of ADA in the diagnosis of pleural TB were 92%, 90%, 9.03, 0.10, and 110.08, respectively. 40 The use of the ADA2 isoenzyme assay has been found to increase the specificity up to 98.6% but its use tends to be restricted to the research setting. 3 It may assist in differentiating TB from malignancy in some cases. On the rare occasion that TB and malignancy coincide, a pleural biopsy would still be required despite use of the isoenzyme assay. 41 Early in TB pleural disease the ADA levels may be low, however, repeat thoracentesis usually demonstrates the expected elevation along with increasing lymphocyte counts. 42 ADA levels may be falsely low in elderly patients and current smokers with TB pleurisy, and falsely elevated in rheumatoid pleural effusions, bacterial pleural infection, mesothelioma, lung cancer and haematological malignancies especially lymphoma.
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| Gamma interferon
Gamma interferon (IFN-g) is a cytokine released by activated CD 1 4 T lymphocytes in the normal immune response to TB infection, which augments the mycobactericidal activity of macrophages. The presence of unstimulated IFN-g in pleural fluid at a concentration of greater than 140 pg/mL has a sensitivity and specificity of 94% and 92% for TB pleural effusion. These values increased to 95% and 96% when the cut-off value of 240 pg/mL was used. 44, 45 In a metaanalysis, the sensitivity of the IFN-g assay for TB pleural effusion was 89%, and the specificity 97%. 46 There is evidence that the IFN-g assay may be superior to ADA for the detection of TB pleural effusion, however, in practice there are several limiting factors which preclude its widespread use, such as the high cost and complexity of ELISA testing in high-prevalence regions, as well as lack of availability of standardised assays. 14 It is noteworthy that the interferon gamma release assays (IGRAs) such as the QuantiFERON-TB Gold (QIAGEN) and T-SPOT.TB (Oxford Immunotec) which make use of stimulating antigens, show no superiority over the measurement of unstimulated IFN-g levels for the detection of TB in pleural fluid. It is inferred that the lymphocytes in TB effusions are maximally stimulated, and thus the IGRAs are unsuitable for the detection of TB pleural disease.
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| Detection of mycobacteria
With the increasing prevalence of resistance to anti-TB drugs, obtaining microbiological proof of the organism and its drug sensitivity profile is becoming paramount. Sputum samples have a modest yield in pleural TB. If spontaneous sputum is negative, induced sputum samples yield positive cultures in up to 55% of patients without evidence of parenchymal involvement on chest radiograph. 50 The role of sputum nucleic acid amplification tests (NAAT) such as Xpert MTB/RIF (Cepheid) has yet to be elucidated but can be expected to be similar to that of sputum culture. 51 Where sputum analysis fails, samples may be acquired through fiberoptic bronchoscopy in patients with parenchymal lesions. 52 The yield of pleural fluid microscopy for Mtb is less than 10%, with the exception of HIV positive patients and those with empyema, where the yield is increased up to 20%. 13 The yield of pleural fluid culture is dependent on the method used. Liquid culture media improve the sensitivity from 30% to 70% over solid media with the additional benefit of having a faster time to positivity (2 weeks compared to 6 weeks). 53 The yield of pleural fluid culture cannot be increased by concentrating higher volumes of pleural fluid. 54 HIV positive patients are more likely to have positive pleural fluid cultures, likely due to ineffective bacterial clearance from the pleural space. 54 Loculated TB pleural effusions have a culture positivity rate of 69%, and in general, cultures are more likely to be positive if the effusion is neutrophil predominant or the sample is acquired early in the course of the disease. 7, 55 NAATs on pleural fluid have a sensitivity of 62%-76.5% and specificity of 91%-98% in two previous meta-analyses. 56, 57 The subsequent introduction of Xpert MTB/RIF did not improve the utility of NAATs in pleural TB, demonstrating a sensitivity of between 25% and 49% and a specificity of 99%-100%, and at present they are not considered part of the diagnostic algorithm. [58] [59] [60] The combination of sputum and pleural fluid cultures improves the overall diagnostic accuracy, with a combined yield of almost 79%-80%. 7, 54 In general, the presence of caseating granulomas containing acid-fast bacilli on histological specimens is diagnostic. 13 Pleural biopsy has a culture positivity rate of 76%, with the additional possibility of detecting caseating granulomas, which can be sufficient evidence for treatment initiation in TB-endemic areas even in the absence of demonstrable bacilli. 5, 28 Tissue can be acquired through various means including closed pleural biopsy, medical thoracoscopy, video-assisted thoracoscopic surgery and open surgical biopsy depending on local availability and expertise. Ultrasound-guided closed pleural biopsy has a 90% yield in TB-endemic regions. 54 Abrams needle is favoured over Tru-cut needle for these procedures. 60 Pleural biopsies taken under direct visualisation via thoracoscopy have a sensitivity of up to 100% for TB pleuritis. 5, 52 The addition of closed pleural biopsy to thoracentesis increased the yield for TB pleural disease from 77.8% to 88.9%. 32 In another study, a combined ADA of more than 50 IU/L, lymphocyte/neutrophil ratio more than 0.75 plus closed pleural biopsy reached 93% sensitivity and 100% specificity. 5 In summary, a definitive diagnosis of TB pleural effusion is made via the demonstration of Mtb bacilli in sputum, pleural fluid, or pleural biopsy specimens. In the absence of microbiological evidence, the diagnosis relies heavily on the pretest probability for TB in the individual patient. In high TB endemic areas or situations of recent exposure of the patient, a lymphocyte predominant exudate with a high ADA with or without granulomas on a pleural biopsy specimen is sufficient evidence to initiate treatment. In populations with a low prevalence of TB, histological examination is almost universally necessary. In patients who have had at least one nondiagnostic aspiration, repeat aspiration should be considered as this increases the diagnostic yield for TB. 32 In areas where the prevalence of drug resistance is high or there is recent exposure to drug-resistant TB, every attempt must be made to identify the bacillus and its drug susceptibility profile. In this case we would suggest a lower threshold for performing a pleural biopsy. Figure 3 summarises a suggested diagnostic algorithm.
FIGU RE 3 A suggested algorithm for the diagnostic evaluation of a patient who presents with a clinical and radiological suspicion of pleural TB.
Initial microbiological confirmation includes positive smear microscopy, Xpert MTB/RIF or positive culture on sputum or pleural fluid. *Pretest probability includes consideration of high local TB prevalence over 125 per 100 000 population, previous TB exposure, and immunosuppression. **High risk includes a local prevalence > 6% of new cases of TB, previous TB, known exposure to drug resistant TB
| MAN AGE MEN T
The recommended therapy for extrapulmonary TB (excluding TB meningitis which requires a longer duration of therapy) is the standard 6 month regimen consisting of a two month intensive phase of Rifampicin, Isoniazid, Pyrazinamide, Ethambutol (RHZE) in fixed dose combination, followed by a four month continuation phase with RH. 61, 62 On the basis of the theory that TB pleural effusions are paucibacillary, shorter regimens have been administered and seem to show a low relapse rate. 14 Furthermore, paucibacillary disease has a much lower chance of spontaneous resistance mutations so that single drug resistance might easily be overcome with the current multidrug regimens. However, currently shorter regimens are not recommended and the management of drug resistant TB remains complex. 2 In such cases, susceptibility testing is highly recommended to make informed decisions. WHO guidelines for drug resistant TB include the selection of at least five drugs that are likely to be effective, with additional add-on drugs when necessary, for a duration of 20 months. A new short-course regimen is only 9-12 months in selected patients, with an expected success rate of 90%. 2 Where HIV positive patients with TB
have not yet initiated antiretroviral therapy (ART), it should be started within 8 weeks of TB treatment unless the CD 1 4 cell count is less than 50 cells/mm 3 , in which case ART should be expedited to within 2 weeks of anti-TB therapy. 61 Patients who are on both ART and anti-TB therapy may experience immune reconstitution inflammatory syndrome (IRIS) as well as significant drug-drug interactions, especially if on protease inhibitor-based regimens. Such patients require the attention of experienced centers. 63 The time to resolution of fever with appropriate therapy can range from 2 weeks to 2 months, though therapeutic thoracentesis may reduce the interval and may be repeated at least once. 14 The time to radiographic resolution ranges from 6 to 12 weeks or longer, dependent on the size of the effusion and the burden of disease. 3 Corticosteroid therapy is beneficial in TB meningitis and selected patients with TB pericarditis, and some evidence suggests that in pleural effusions they can shorten the duration of fever, time to fluid resorption and reduce residual pleural thickening. [64] [65] [66] However, the quality of evidence remains low, and the adverse effects of corticosteroids are an important concern. At present corticosteroids are not routinely recommended in TB pleural effusions. 65 Only patients with sputa positive for Mtb need be isolated at the start of therapy. Occasionally an initial paradoxical worsening in condition is noted after therapy is initiated, independent of HIV status. This phenomenon has especially been noted in young, previously healthy, male patients with subpleural nodules on initial CT scans. 31 Residual pleural thickening post therapy with reductions in forced vital capacity has been noted in up to 50% of patients, especially where there have been loculations, but from experience in high prevalence areas the rate of residual pleural disease that can limit quality of life is low. 14 Therapeutic thoracentesis has been associated with a rapid improvement in dyspnoea, minor improvements in lung function and less residual pleural thickening, however, the clinical and long term implications of these differences remains unclear. 3, 14 Residual pleural thickening may be reduced by instillation of an intrapleural fibrinolytic in loculated effusions. 66 Surgical intervention may be indicated in patients with loculated effusions or empyema, where a chronic purulent exudate is present or a thick calcified pleural rind has developed. Surgical decortication for a fibrothorax is indicated in symptomatic subjects where a pleural peel has been present for more than 4-6 weeks.
| CO NCL US I ON
Extrapulmonary TB, of which the pleura is the second most common site, presents a particular problem in regions with high HIV prevalence. The emergence of drug resistance threatens control and it is advised that in high prevalence areas all new cases of TB have drug sensitivity testing performed at diagnosis, even using biopsy specimens if necessary. The understanding of TB pleural disease has evolved from a delayed hypersensitivity reaction with a lymphocytepredominant effusion, to lymphocyte-driven immune response to a paucibacillary infection. A small subset of patients will develop complications including TB empyema and fibrothorax. Though the natural history of pleural TB is resolution, anti-TB treatment is always indicated as up to 80% of patients have concomitant pulmonary parenchymal lesions with a substantial number progressing to active pulmonary TB either immediately or later in life. The pleural disease can result in residual functional and anatomical abnormalities, and some interventions such as early therapeutic thoracentesis have shown promise in addressing these, however, further investigation is required to identify the individuals at risk and to establish a clear benefit in those affected.
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